The value of engaging a single CDMO for comprehensive biologics services from discovery to GMP manufacturing

white paper

Biologics

A large portion of innovative companies are in discovery, preclinical or early clinical stages with therapeutics aimed at oncology and infectious diseases. There is promising growth in overall biologics therapies, driven by increased funding and growing patient demand.

However, emerging innovators do not possess the necessary infrastructure in-house and are underserved by current manufacturing landscape that is not customized for early phase pipeline needs.

Partnering with a single CDMO can increase speed to market, ensure production capacity and avoid costly and time-consuming tech transfers.

Download our white paper for insights on:

How our integrated analytical, process development and manufacturing teams can streamline drug development
How we balance the science of discovery with the engineering mindset for manufacturing
How we evolve with your needs with our end-to-end CDMO support from discovery to GMP manufacturing

Download the White Paper

Ready to move from idea to impact?

Whether you have a question for our team or an opportunity you’re eager to pursue, one of our experts can help you get started.

More from Curia

article

Trends and Challenges in the Pharmaceutical Industry

Significant changes have taken place in the life sciences industry over the past few years. Since the Covid-19 pandemic, the U.S. government has urged biotech and pharmaceutical companies to increase domestic production in order to secure the drug su...

white paper

Continuous Flow - An Emerging Alternative

With the growing complexity of drug molecules and the need to involve newer and harsher reaction conditions that were once thought of as unfriendly in process chemistry, continuous flow chemistry and processing offer a proven alternative pathway.